North China Pharmaceutical's (SHA:600812) unit, North China Pharmaceutical Huakun Hebei Biotechnology, received a drug registration certificate from China's National Medical Products Administration for its emtricitabine alafenamide tenofovir tablets (II), according to a Sept. 27 disclosure on the Shanghai Stock Exchange.
The drug is used in combination with other antiretroviral drugs to treat human immunodeficiency virus or HIV type 1 infection in adults and adolescents.
The certificate is valid until Sept. 18, 2029, the pharmaceutical company said.
Price (RMB): ¥5.65, Change: ¥+0.51, Percent Change: +9.92%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments